Dr. Minjun Chen received his Ph.D. in pharmaceutical science from Zhejiang University, Hangzhou, China. He worked as an assistant and then associate professor in the school of pharmacy, Shanghai Jiaotong University, Shanghai. He also worked as a postdoctoral fellow for University of Medicine and Dentistry of New Jersey (UMDNJ) in Piscataway, New Jersey and the FDA's national center for toxicological research (NCTR) in Jefferson, Arkansas. Currently, Dr. Chen is a principal investigator working at the Division of Bioinformatics and Biostatics of the FDA’s NCTR. Dr. Chen has published over 50 peer-reviewed manuscripts in prestigious journals such as Hepatology, Clinical Pharmacology & Therapeutic, and Toxicological Science and was invited to contribute review paper by Journal of Hepatology and Drug Discovery Today. He received the FDA award for outstanding junior investigator in 2012 and the NCTR scientific achievement award in 2014. His primary research interests encompass bioinformatics, drug safety, biomarker discovery, and toxicogenomics.

​

His current research focus is in two areas: (1) development of the Liver Toxicity Knowledge Base (LTKB) to address the public health concerns related to drug-induced liver injury (DILI), and (2) identification of predictive biomarkers for the prognostics and predicting the outcome of chemotherapy of breast cancer patients for personalized medication.

 

Email :  NCTRResearch@fda.hhs.gov